Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context
← catalyst calendarNCT06487078 · readout in 834 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
90estimated
Sites
31
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-20 | actual | When the study began enrolling |
| Primary completion | 2028-11-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- ALK+ Non-Small-Cell Lung Carcinoma
Intervention
- Drug: Lorlatinib — also filed as PF-06463922
Primary outcome
what the primary-completion date above is the date OFProgression-Free Survival (PFS)
measured From time of Study Start up to 25 months
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed